BioSpace News Archive

Medigene AG presents novel preclinical data of their MDG2011 program lead candidates which are optimal affinity Kirsten rat sarcoma viral oncogene homologue mutation -specific T cell receptors targeting human leukocyte antigens A*11, in combination with a PD1-41BB costimulatory switch protein at the Society for Immunotherapy of Cancer 2023 November 1-5, 2023, in San Diego, USA.

Boehringer Ingelheim and Carelon Research have conducted a validation study of the Klinrisk model, a machine-learning tool developed to predict the risk of chronic kidney disease progression at all stages of the disease.

Astellas Pharma Inc. announced results from the GATHER2 Phase 3 clinical trial, demonstrating IZERVAY™ continued to reduce the rate of geographic atrophy lesion growth for both every month and every-other-month dosing vs. sham through 2 years of treatment in patients with GA secondary to age-related macular degeneration.

KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application for KGX101.

Promontory Therapeutics Inc. presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death in cancer cells.

Apellis Pharmaceuticals, Inc. announced data from the GALE extension study following 3 years of continuous treatment with SYFOVRE®, the first-ever FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration.

Maze Therapeutics announced findings from preclinical studies demonstrating the potential of a novel APOL1 inhibitor to reverse disease manifestations of APOL1 kidney disease in a chronic APOL1 kidney disease mouse model.

Vera Therapeutics, Inc. announced the presentation of three posters – including an additional analysis of week 36 data from the Phase 2b ORIGIN study demonstrating resolution of hematuria in the majority of patients – on the Company’s product candidate atacicept in patients with immunoglobulin A nephropathy at the American Society of Nephrology Kidney Week 2023, in Philadelphia, PA.

Bayer announced new interim, real-world data on Kerendia® that complement the hyperkalemia and safety data in its pivotal trials.

Candel Therapeutics, Inc. will present two posters during the 2023 Society for Immunotherapy of Cancer Annual Meeting in San Diego focused on the enLIGHTEN™ Discovery Platform.